Global Pancreatic Cancer Treatment Market

Pancreatic Cancer Treatment Market Size, Share, Growth Analysis, By Treatment Type(Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy), By Diagnosis(Blood Test, Biopsy, Imaging Tests, Others), By Route of Administration(Oral, Parenteral, Others), By End-User(Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35I2262 | Region: Global | Published Date: July, 2001
Pages: 165 | Tables: 149 | Figures: 78

Pancreatic Cancer Treatment Market News

  • In January 2022, for pancreatic cancer treatment, the U.S. Food and Drug Administration (FDA) gave orphan drug status to multitargeted T-cell therapy. This therapy has shown the potential to elicit sustained responses in individuals with advanced or metastatic pancreatic cancer when combined with chemotherapy as a first-line therapeutic option.

     

  • In February 2022, Eli Lilly and Company and UNICEF declared a collaboration aimed at improving healthcare facilities for around 10 million children and adolescents suffering from non-communicable diseases.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Pancreatic Cancer Treatment Market size was valued at USD 2.15 billion in 2022 and is poised to grow from USD 2.48 billion in 2023 to USD 6.85 billion by 2031, growing at a CAGR of 15.7% in the forecast period (2024-2031).

The pancreatic cancer treatment market is fiercely competitive, and few major companies dominate it. The competition is getting more intense due to the presence of major market players. The market participants are implementing methods including increased R&D spending, mergers, acquisitions, and product developments. 'Eli Lilly and Company', 'F. Hoffmann-La Roche Ltd.', 'Celgene Corporation', 'Novartis AG', 'Pfizer Inc.', 'Amgen Inc.', 'Merck & Co., Inc.', 'Bayer AG', 'Bristol-Myers Squibb Company', 'AstraZeneca', 'AbbVie Inc.', 'Teva Pharmaceutical Industries Ltd.', 'Sanofi S.A.', 'Takeda Pharmaceutical Company Limited', 'Ipsen S.A.', 'Gilead Sciences, Inc.', 'Daiichi Sankyo Company, Limited', 'Boehringer Ingelheim International GmbH', 'Jazz Pharmaceuticals, Inc.', 'Exelixis, Inc'

According to estimates, the market would develop faster due to the increased incidence of cancer. Genetic anomalies including the BRCA2 gene mutation, Lynch syndrome, and familial atypical mole-malignant melanoma (FAMMM) syndrome may increase the risk of cancer running in the family. The dynamics of the market will be impacted by the rising rates of diabetes and obesity, which will raise the risk of pancreatic cancer.

Increase in R&D activities: Rise in the R&D activities is fueling the market expansion. This will present advantageous chances for the expansion of the market for treatments for pancreatic cancer. Along with this, an increase in drug releases and approvals will speed up the market's expansion.  

With the highest revenue share in 2022, North America dominated the pancreatic cancer treatment market. This region's dominance is primarily due to improved healthcare infrastructure, widespread adoption of pancreatic treatment procedures, and the presence of a large target population. Furthermore, the rising incidence of pancreatic cancer is driving up demand for treatment options. By authorising medications in the clinical phase and so hastening clinical advances, the USFDA is also taking steps to boost the development of the pancreatic cancer treatment market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Pancreatic Cancer Treatment Market

Report ID: SQMIG35I2262

$5,300
BUY NOW GET FREE SAMPLE